An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The objective of the study is to assess long term safety and tolerability of patients enrolling from prior Sutent clinical studies. Duration of clinical benefit will be assessed for patients enrolling from protocol A6181111; PNET.
duration of study
Pfizer CT.gov Call Center
United States: Food and Drug Administration
|Pfizer Investigational Site||Atlanta, Georgia 30342|
|Pfizer Investigational Site||Springfield, Illinois 62701-1014|
|Pfizer Investigational Site||Houston, Texas 77030|
|Pfizer Investigational Site||Richmond, Virginia 23249|
|Pfizer Investigational Site||Cedar Rapids, Iowa 52403|
|Pfizer Investigational Site||Columbia, Missouri 65201|
|Pfizer Investigational Site||Las Vegas, Nevada 89128|
|Pfizer Investigational Site||Eugene, Oregon 97401|